Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05961644Phase 2Recruiting

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Role: collaborator

NCT04346680Not ApplicableUnknown

Intraoperative ADSC Administration During Nerve Release

Role: lead

NCT03676569Phase 1Completed

Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy

Role: lead

NCT03296501Phase 1Unknown

Intraspinal Transplantation of Autologous ADRC in ALS Patients

Role: lead

All 4 trials loaded